200 related articles for article (PubMed ID: 29211298)
1. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.
Vaarwerk B; van der Lee JH; Breunis WB; Orbach D; Chisholm JC; Cozic N; Jenney M; van Rijn RR; McHugh K; Gallego S; Glosli H; Devalck C; Gaze MN; Kelsey A; Bergeron C; Stevens MCG; Oberlin O; Minard-Colin V; Merks JHM
Cancer; 2018 Mar; 124(5):1016-1024. PubMed ID: 29211298
[TBL] [Abstract][Full Text] [Related]
2. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
[TBL] [Abstract][Full Text] [Related]
3. [The treatment results in children with malignant mesenchymal tumors according to the protocols of the International Society of Pediatric Oncology (SIOP)].
López Pérez J; Melero Moreno C; Vivanco Martínez JL; Torres Valdivieso MJ; Cela de Julián E
An Esp Pediatr; 1996 Jun; 44(6):557-60. PubMed ID: 8849098
[TBL] [Abstract][Full Text] [Related]
4. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS
Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229
[TBL] [Abstract][Full Text] [Related]
5. Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies.
Orbach D; Mosseri V; Gallego S; Kelsey A; Devalck C; Brenann B; van Noesel MM; Bergeron C; Merks JH; Rechnitzer C; Jenney M; Minard-Colin V; Stevens M
Head Neck; 2017 Jan; 39(1):24-31. PubMed ID: 27459057
[TBL] [Abstract][Full Text] [Related]
6. Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95.
Jenney M; Oberlin O; Audry G; Stevens MC; Rey A; Merks JH; Kelsey A; Gallego S; Haie-Meder C; Martelli H
Pediatr Blood Cancer; 2014 Feb; 61(2):217-22. PubMed ID: 23997024
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India.
Roy S; Pathy S; Mohanti BK; Chander S; Biswas A
J Pediatr Hematol Oncol; 2017 Mar; 39(2):e62-e68. PubMed ID: 28060113
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
[TBL] [Abstract][Full Text] [Related]
9. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.
Hayes-Jordan A; Stoner JA; Anderson JR; Rodeberg D; Weiner G; Meyer WH; Hawkins DS; Arndt CA; Paidas C;
J Pediatr Surg; 2008 May; 43(5):831-6. PubMed ID: 18485948
[TBL] [Abstract][Full Text] [Related]
10. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Tian J; Gupta AA; Wolden SL; Routh JC; Casey DL; Dasgupta R; Hawkins DS; Rodeberg DA
Int J Cancer; 2020 Sep; 147(5):1419-1426. PubMed ID: 32012255
[TBL] [Abstract][Full Text] [Related]
12. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Rodeberg DA; Stoner JA; Hayes-Jordan A; Kao SC; Wolden SL; Qualman SJ; Meyer WH; Hawkins DS
J Clin Oncol; 2009 Aug; 27(22):3705-11. PubMed ID: 19470937
[TBL] [Abstract][Full Text] [Related]
14. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.
Minard-Colin V; Walterhouse D; Bisogno G; Martelli H; Anderson J; Rodeberg DA; Ferrari A; Jenney M; Wolden S; De Salvo G; Arndt C; Merks JHM; Gallego S; Schwob D; Haie-Meder C; Bergeron C; Stevens MCG; Oberlin O; Hawkins D;
Pediatr Blood Cancer; 2018 Sep; 65(9):e27096. PubMed ID: 29781567
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
[TBL] [Abstract][Full Text] [Related]
16. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study.
Rousseau P; Flamant F; Quintana E; Voute PA; Gentet JC
J Clin Oncol; 1994 Mar; 12(3):516-21. PubMed ID: 7509854
[TBL] [Abstract][Full Text] [Related]
17. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
[TBL] [Abstract][Full Text] [Related]
18. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
[TBL] [Abstract][Full Text] [Related]
19. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Orbach D; Rey A; Oberlin O; Sanchez de Toledo J; Terrier-Lacombe MJ; van Unnik A; Quintana E; Stevens MC
J Clin Oncol; 2005 Jul; 23(19):4363-71. PubMed ID: 15994146
[TBL] [Abstract][Full Text] [Related]
20. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
